logo-loader
viewNovaBay Pharmaceuticals

Amazon now carrying NovaBay Pharmaceuticals’ Avenova eye-care product; shares skyrocket

Avenova is available without a prescription on Amazon's new direct direct-to-consumer online channel

eye
The Avenova spray removes bacteria and debris on and around the eyelid that contribute to bacterial eye infections

Shares of NovaBay Pharmaceuticals Inc (NYSEAMERICAN:NBY) increased more than six-fold Monday after the company announced that its Avenova eye-care product is now available without a prescription at Amazon.com.

The Emeryville, California-based biopharmaceutical company said customers can purchase Avenova on Amazon.com Inc's (NASDAQ:AMZN) new direct direct-to-consumer online channel.

NovaBay’s stock exploded 541% to $2.04 a share on heavy volume Monday afternoon. 

Treating dry eyes

Avenova, a spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market, the company said.

“While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye-care specialists, patients and physicians have asked for greater accessibility to the product," said CEO Justin Hall. "In response, we are launching our new US direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price."

Avenova, or Avenova Direct as the online version is called, is available from Amazon in the US in a 20 milliliter size for $29.99, the company said.

-- updates stock price --- 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: NovaBay Pharmaceuticals

Price: 0.6234 USD

NYSEMKT:NBY
Market: NYSEMKT
Market Cap: $17.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene working hard to manufacture genetic analyzer that...

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Jack Regan tells Proactive the biotechnology company is working as hard as it can to get its diagnostic instrument that can be configured to detect threats like Coronavirus, into the hands of people who need it. Regan also explained the...

15 hours, 11 minutes ago

2 min read